Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

Kim, Dong‐Hee; Touros, Alexis; Kim, W. Ray

doi:10.1016/j.cld.2017.08.010

Cited by 172 publications

(122 citation statements)

References 44 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…In particular, compared to the HFD group, all CO/TC treatments significantly down-regulated the mRNA expression level of IL-6 ( Figure 1h). In addition, it is well known that nonalcoholic fatty liver disease is strongly associated with MetS [26]. Consequently, the effects of CO/TC formulations on hepatic steatosis were examined.…”

Section: Co/tc Formulations Attenuated Symptoms Of Hfd-induced Metabomentioning

confidence: 99%

The Regulatory Effects of a Formulation of Cinnamomum osmophloeum Kaneh and Taiwanofungus camphoratus on Metabolic Syndrome and the Gut Microbiome

Wang

Hsieh

Kumar

et al. 2020

Plants

View full text Add to dashboard Cite

The number of people with metabolic syndrome (MetS) is increasing year by year, and MetS is associated with gut microbiota dysbiosis. The demand for health supplements to treat or prevent MetS is also growing. Cinnamomum osmophloeum Kaneh (CO) and Taiwanofungus camphoratus (TC) are endemic to Taiwan. Both have been shown to improve the symptoms of MetS, such as dyslipidemia and hyperglycemia. Herein, we investigated the effect of CO, TC and their formulations on diet-induced obese mice. Male C57BL/6J mice were fed with a high-fat diet (HFD) for 10 weeks to induce MetS. After that, the mice were fed with HFD supplemented with CO, TC, and various CO/TC formulations, respectively, for 14 weeks. The changes in physiological parameters and the composition of the gut microbiome were investigated. The results indicated that CO, TC, and their formulations effectively reduced hyperglycemia, and tended to alleviate MetS in obese mice. Moreover, we also observed that CO, TC, and their formulations improved gut microbiota dysbiosis by decreasing the Firmicutes-to-Bacteroidetes ratio and increasing the abundance of Akkermansia spp. Our results revealed that CO and TC might have potential for use as a prebiotic dietary supplement to ameliorate obesity-related metabolic disorders and gut dysbiosis.

show abstract

Section: Co/tc Formulations Attenuated Symptoms Of Hfd-induced Metabomentioning

confidence: 99%

The Regulatory Effects of a Formulation of Cinnamomum osmophloeum Kaneh and Taiwanofungus camphoratus on Metabolic Syndrome and the Gut Microbiome

Wang

Hsieh

Kumar

et al. 2020

Plants

View full text Add to dashboard Cite

show abstract

“…4,6,7 NAFLD is strongly associated with metabolic syndrome (MetS), the components of which include hypertension, hyperglycemia, abdominal obesity, and dyslipidemia. 8 However, NAFLD is not merely a hepatic manifestation of MetS but rather both a consequence as well a predecessor of MetS. Compared with the general population, NAFLD patients are at increased risk of liverrelated, cardiovascular and all-cause mortality.…”

Section: Introductionmentioning

confidence: 99%

Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations

Kumar¹,

Priyadarshi²,

Anand³

2019

Journal of Clinical and Translational Hepatology

106

112

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a systemic disorder with a complex multifactorial pathogenesis and heterogenous clinical manifestations. NAFLD, once believed to be an innocuous condition, has now become the most common cause of chronic liver disease in many countries worldwide. NAFLD is already highly prevalent in the general population, and owing to a rising incidence of obesity and diabetes mellitus, the incidence of NAFLD and its impact on global healthcare are expected to increase in the future. A subset of patients with NAFLD develops progressive liver disease leading to cirrhosis, hepatocellular carcinoma, and liver failure. NAFLD has emerged as one of the leading causes of cirrhosis and hepatocellular carcinoma in recent years. Moreover, HCC can occur in NAFLD even in absence of cirrhosis. Compared with the general population, NAFLD increases the risk of liverrelated, cardiovascular and all-cause mortality. NAFLD is bidirectionally associated with metabolic syndrome. NAFLD increases the risk and contributes to aggravation of the pathophysiology of atherosclerosis, cardiovascular diseases, diabetes mellitus, and chronic kidney disease. In addition, NAFLD is linked to colorectal polyps, polycystic ovarian syndrome, osteoporosis, obstructive sleep apnea, stroke, and various extrahepatic malignancies. Extended resection of steatotic liver is associated with increased risk of liver failure and mortality. There is an increasing trend of NAFLDrelated cirrhosis requiring liver transplantation, and the recurrence of NAFLD in such patients is almost universal. This review discusses the growing burden of NAFLD, its outcomes, and adverse associations with various diseases. Citation of this article: Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: Growing burden, adverse outcomes and associations. Global burden and rising prevalenceAccording to current estimate, the global prevalence of NAFLD among the general population may be as high as one billion. 2 In a recent meta-analysis of 86 studies, 76

show abstract

“…Importantly, about 30 percent of patients with NAFLD do not present with any systemic metabolic abnormalities (Kim et al. ). However, most patients with NAFLD concurrently present with insulin resistance which is the hallmark (Asrih and Jornayvaz ) in the development of type 2 diabetes mellitus (T2DM) and MetS (Adams et al.…”

Section: Introductionmentioning

confidence: 99%

The long‐term protective effects of neonatal administration of curcumin against nonalcoholic steatohepatitis in high‐fructose‐fed adolescent rats

et al. 2019

View full text Add to dashboard Cite

There is an increased prevalence of nonalcoholic steatohepatitis ( NASH ) in adolescents. The suckling period is developmentally plastic, affecting later health outcomes. We investigated whether neonatal administration of curcumin would provide protection against the development of NASH later in adolescence in rats fed a high‐fructose diet. From postnatal day ( PN ) 6 to PN 21, the pups ( N = 128) were allocated to four groups and orally gavaged daily with either 0.5% dimethyl sulfoxide solution (vehicle control), curcumin (500 mg·kg −1 ), fructose (20%, w/v) or curcumin and fructose combined. All the pups were weaned and half the rats in each group had tap water, whereas the other received fructose (20%) as their drinking fluid ad libitum for 6 weeks. The rats’ liver NASH scores, lipid content, and RNA gene expression ratios of AMPK α and TNF α were determined. Hepatic lipid content was similar across the treatment groups in the males ( P > 0.05, ANOVA ). In the females, the hepatic lipid content in the treatment groups ranged from 2.7 to 4.3%. The livers of male and female rats that had fructose either as neonates and/or postweaning had significantly marked inflammation ( P = 0.0112, Kruskal–Wallis) and fibrosis ( P < 0.0001, ANOVA ) which were attenuated by curcumin. The hepatic gene expression ratios for AMPK α in both sexes were significantly downregulated ( P < 0.0001, ANOVA ), whereas the expression ratios of TNF α were significantly upregulated ( P < 0.0001) in rats fed a high‐fructose diet pre and/or postweaning compared to the other groups. Neonatal curcumin administration is a potential natural pharmacological candidate for the prevention of NASH .

show abstract

Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

Cited by 172 publications

References 44 publications

The Regulatory Effects of a Formulation of Cinnamomum osmophloeum Kaneh and Taiwanofungus camphoratus on Metabolic Syndrome and the Gut Microbiome

The Regulatory Effects of a Formulation of Cinnamomum osmophloeum Kaneh and Taiwanofungus camphoratus on Metabolic Syndrome and the Gut Microbiome

Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations

The long‐term protective effects of neonatal administration of curcumin against nonalcoholic steatohepatitis in high‐fructose‐fed adolescent rats

Contact Info

Product

Resources

About